
    
      This protocol was designed to compare the pharmacokinetic parameters of atazanavir
      administered as atazanavir/ritonavir, 400/100 mg once daily (QD), plus famotidine, 20 mg and
      40 mg twice daily, with the parameters found at the usual clinical dose of
      atazanavir/ritonavir, 300/100 mg QD, without famotidine in HIV-infected participants
      receiving tenofovir disoproxil fumarate and at least 1 other nucleoside reverse transcriptase
      inhibitor.
    
  